🎉 M&A multiples are live!
Check it out!

Nicox Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nicox and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Nicox Overview

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.


Founded

1996

HQ

France
Employees

28

Website

nicox.com

Financials

LTM Revenue $3.7M

LTM EBITDA n/a

EV

$34.1M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nicox Financials

Nicox has a last 12-month revenue of $3.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Nicox achieved revenue of $7.1M and an EBITDA of -$17.4M.

Nicox expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nicox valuation multiples based on analyst estimates

Nicox P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $5.6M $7.1M XXX XXX XXX
Gross Profit $7.8M $3.5M XXX XXX XXX
Gross Margin 138% 49% XXX XXX XXX
EBITDA -$18.6M -$17.4M XXX XXX XXX
EBITDA Margin -330% -244% XXX XXX XXX
Net Profit -$47.0M -$29.8M XXX XXX XXX
Net Margin -835% -418% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nicox Stock Performance

As of April 15, 2025, Nicox's stock price is EUR 0 (or $0).

Nicox has current market cap of EUR 15.7M (or $16.9M), and EV of EUR 31.8M (or $34.1M).

See Nicox trading valuation data

Nicox Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$34.1M $16.9M XXX XXX XXX XXX $-0.26

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Nicox Valuation Multiples

As of April 15, 2025, Nicox has market cap of $16.9M and EV of $34.1M.

Nicox's trades at 9.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Nicox's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Nicox and 10K+ public comps

Nicox Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $34.1M XXX XXX XXX
EV/Revenue 4.8x XXX XXX XXX
EV/EBITDA -2.0x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nicox Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Nicox Valuation Multiples

Nicox's NTM/LTM revenue growth is -100%

Nicox's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Nicox's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Nicox's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Nicox and other 10K+ public comps

Nicox Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 27% XXX XXX XXX XXX
EBITDA Margin -244% XXX XXX XXX XXX
EBITDA Growth -6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 90% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nicox Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nicox M&A and Investment Activity

Nicox acquired  XXX companies to date.

Last acquisition by Nicox was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nicox acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nicox

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Nicox

When was Nicox founded? Nicox was founded in 1996.
Where is Nicox headquartered? Nicox is headquartered in France.
How many employees does Nicox have? As of today, Nicox has 28 employees.
Is Nicox publicy listed? Yes, Nicox is a public company listed on PAR.
What is the stock symbol of Nicox? Nicox trades under ALCOX ticker.
When did Nicox go public? Nicox went public in 1999.
Who are competitors of Nicox? Similar companies to Nicox include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Nicox? Nicox's current market cap is $16.9M
What is the current revenue of Nicox? Nicox's last 12-month revenue is $3.7M.
What is the current EV/Revenue multiple of Nicox? Current revenue multiple of Nicox is 9.1x.
What is the current revenue growth of Nicox? Nicox revenue growth between 2023 and 2024 was 27%.
Is Nicox profitable? Yes, Nicox is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.